CompletedPhase 1ACTRN12605000468628
A pharmacokinetic study to assess the comparative bioavailability of 17-B-estradiol from Metered-Dose Transdermal Sprays (MDTS) and Estraderm 50 patches as hormone replacement therapy in postmenopausal women.
Sponsor
FemPharm Pty Ltd and/or Acrux DDS Pty Ltd
Enrollment
12 participants
Start Date
Feb 21, 2000
Study Type
Interventional
Conditions
Eligibility
Sex: FemalesMin Age: 18 Yearss
Plain Language Summary
Simplified for easier understanding
This study compares different skin spray formulations to see how well they deliver estradiol, a form of estrogen, into the bloodstream. It is open to healthy postmenopausal women aged 18 and older. Participation involves applying sprays to the skin and providing blood samples.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Estradiol Metered-Dose Transdermal Sprays (MDTS) vs Estraderm 50 patches for 6-days.
Estradiol Metered-Dose Transdermal Sprays (MDTS) vs Estraderm 50 patches for 6-days.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000468628